Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial: uPAR-PET/MR in Patients With Newly Diagnosed Prostate Cancer; Non-invasive Characterization of Tumor Aggressiveness

Next Previous
X
Search
Trial Profile

Phase II Trial: uPAR-PET/MR in Patients With Newly Diagnosed Prostate Cancer; Non-invasive Characterization of Tumor Aggressiveness

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gallium-68 NOTA AE105 (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use

    • Most Recent Events

    • 13 Feb 2024 According to Curasight media release, first interim data is expected Q3 2024.
    • 22 Jan 2024 According to a Curium Pharma media release, The trial design is informed from research and earlier studies with uTRACE as well as protocol discussions with the US Food and Drug Administration (FDA). This phase 2 trial is part of the development framework agreed under the deal with Curium.
    • 11 Oct 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top